HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00088634

Lurasidone for schizophrenia: safety and effectiveness

About this title

A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

Read the official source — NCT00088634
Medication studyAges 18–64United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Listed locations
Birmingham and 21 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study clarity

Study information

Study start dateMay 2004
Recruitment status
Completed
Enrollment listed in the registry
180
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 64 Years
Official registry ID
NCT00088634
Official title
Show the full official title

A Double-blind Fixed-dose Study of Lurasidone (SM-13496) and Placebo in the Treatment of Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Birmingham · Little Rock · Cerritos

16 more locations
  • Garden Grove
  • La Mesa
  • San Diego
  • Upland
  • Washington D.C.
  • North Miami
  • Tampa
  • Atlanta
  • Hoffman Estates
  • Las Vegas
  • Clementon
  • Philadelphia
  • Austin
  • Bellaire
  • DeSoto
  • Falls Church
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Lurasidone and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies